Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Mortality due to Rabies
4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries
4.2.3 Growing Pet Management technological Advancements and Services
4.3 Market Restraints
4.3.1 Low Immunization Rates in Dogs
4.3.2 Lack of Awareness and Negligence by Government and Public
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Baby Hamster Kidney (BHK)
5.1.2 Purified Chick Embryo Cell Rabies Vaccine
5.1.3 Vero Cell Rabies Vaccine
5.1.4 Other Product Types
5.2 By Vaccination Type
5.2.1 Pre-Exposure Vaccination (PEV)
5.2.2 Post-Exposure Prophylaxis (PEP)
5.3 By End-User
5.3.1 Animals
5.3.2 Humans
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 France
5.4.2.2 Germany
5.4.2.3 United Kingdom
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Berna Biotech Ltd
6.1.2 GlaxoSmithKline plc
6.1.3 Merck & Co Inc
6.1.4 Novartis International AG
6.1.5 Pfizer Inc
6.1.6 Sanofi SA
6.1.7 Zoetis Inc.
6.1.8 Elanco
6.1.9 Virbac


7 MARKET OPPORTUNITIES AND FUTURE TRENDS